{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Arm&page=13",
    "query": {
      "intervention": "Single Arm",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 9906,
    "total_pages": 991,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Arm&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Arm&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T03:38:05.627Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01852565",
      "title": "Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Darapladib",
          "type": "DRUG"
        },
        {
          "name": "Diltiazem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-05-14",
      "completion_date": "2013-09-30",
      "has_results": false,
      "last_update_posted_date": "2017-07-13",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01852565"
    },
    {
      "nct_id": "NCT04379492",
      "title": "A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "COVID19",
        "Sars-CoV2",
        "SARS-Cov-2"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-05-05",
      "completion_date": "2020-09-25",
      "has_results": false,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04379492"
    },
    {
      "nct_id": "NCT06616844",
      "title": "IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Wound Heal",
        "Ulcer"
      ],
      "interventions": [
        {
          "name": "InnovaMatrix® AC",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "ConvaTec Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 235,
      "start_date": "2025-02-12",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 21,
      "location_summary": "Fresno, California • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06616844"
    },
    {
      "nct_id": "NCT02560298",
      "title": "Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anal Basaloid Carcinoma",
        "Anal Canal Cloacogenic Carcinoma",
        "Anal Squamous Cell Carcinoma",
        "Metastatic Anal Canal Carcinoma",
        "Recurrent Anal Canal Carcinoma",
        "Stage IIIB Anal Canal Cancer",
        "Stage IV Anal Canal Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2016-08-23",
      "completion_date": "2023-08",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02560298"
    },
    {
      "nct_id": "NCT02266563",
      "title": "Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Traumatic Brain Injury",
        "Chronic Traumatic Encephalopathy",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Amyvid PET Scan",
          "type": "DRUG"
        },
        {
          "name": "T807 PET scan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Samuel Gandy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "MALE",
        "summary": "40 Years to 85 Years · Male only"
      },
      "enrollment_count": 46,
      "start_date": "2015-01",
      "completion_date": "2017-12-21",
      "has_results": false,
      "last_update_posted_date": "2019-05-02",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02266563"
    },
    {
      "nct_id": "NCT07840287",
      "title": "A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus (SLE)",
        "Cutaneous Lupus Erythematosus (CLE)"
      ],
      "interventions": [
        {
          "name": "Enpatoran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "18 Years to 76 Years"
      },
      "enrollment_count": 404,
      "start_date": "2026-10-15",
      "completion_date": "2031-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 1,
      "location_summary": "Billerica, Massachusetts",
      "locations": [
        {
          "city": "Billerica",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07840287"
    },
    {
      "nct_id": "NCT05335993",
      "title": "A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Recurrent Epithelial Cancer of Ovary",
        "Recurrent Epithelial Ovarian Cancer",
        "Recurrent Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Recurrent Carcinoma of Ovary",
        "Adenocarcinoma of Ovary"
      ],
      "interventions": [
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CanariaBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2022-07-25",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 3,
      "location_summary": "Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05335993"
    },
    {
      "nct_id": "NCT03036930",
      "title": "Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Papillomavirus Infection",
        "Human Papillomavirus-Related Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "HPV Self-Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Recombinant Human Papillomavirus Nonavalent Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 51,
      "start_date": "2017-06-23",
      "completion_date": "2027-03-10",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03036930"
    },
    {
      "nct_id": "NCT03465592",
      "title": "Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma",
        "Solid Tumor, Adult",
        "Solid Tumor, Childhood"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Months to 40 Years"
      },
      "enrollment_count": 39,
      "start_date": "2018-05-01",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 4,
      "location_summary": "St. Petersburg, Florida • Baltimore, Maryland • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03465592"
    },
    {
      "nct_id": "NCT02595892",
      "title": "Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Serous Tumor",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 70,
      "start_date": "2016-08-25",
      "completion_date": "2027-08-05",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-23T03:38:05.627Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595892"
    }
  ]
}